HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N-methyl-1,2-diphenylethanolamine

Also Known As:

MDPE

Networked: 8 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - N-methyl-1,2-diphenylethanolamine: 8
- Alcohols: 595
  - Ethanol: 23169
    - Ethanolamines: 16
      - N-methyl-1,2-diphenylethanolamine: 8
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - N-methyl-1,2-diphenylethanolamine: 8

Experts

1.	Falissard, Bruno: 1 article (01/2022)
2.	Glangeaud-Freudenthal, Nine Mc: 1 article (01/2022)
3.	Gressier, Florence: 1 article (01/2022)
4.	Sutter-Dallay, Anne-Laure: 1 article (01/2022)
5.	Chen, Yi: 1 article (01/2021)
6.	Guo, Lei: 1 article (01/2021)
7.	He, Ling: 1 article (01/2021)
8.	Li, Zhenzhou: 1 article (01/2021)
9.	Ma, Shuqin: 1 article (01/2021)
10.	Ni, Xinli: 1 article (01/2021)

Related Diseases

1.	Hypotension (Low Blood Pressure) 12/01/2019 - "Secondary outcomes included the incidence of bradycardia, hypertension, hypotension, severe hypotension, hypotensive episodes, number of rescue top-ups, hemodynamic performance error including median performance error (MDPE), and median absolute performance error (MDAPE). " 10/09/2023 - "As the prophylactic norepinephrine dosage increased, the incidence of postspinal anesthesia hypotension declined (p < 0.001), and SBP remained stable relative to baseline (median performance error [MDPE], p < 0.001; median absolute performance error [MDAPE], p = 0.001). " 01/01/2021 - "With increasing prophylactic doses of norepinephrine, the incidence of postspinal anesthesia hypotension decreased (p < 0.001), SBP was maintained closer to the baseline (MDPE, p < 0.001; MDAPE, p = 0.001), and the total additional bolus of norepinephrine decreased (p < 0.001). " 01/01/2021 - "Secondary outcomes included the overall stability of SBP control versus baseline (median performance error [MDPE] and median absolute performance error [MDAPE]), the dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients, other adverse events (bradycardia, nausea, vomiting, hypertension, and the total additional bolus of norepinephrine and atropine), and neonatal outcomes (blood gas values and Apgar scores). "
2.	Hypertension (High Blood Pressure) 12/01/2019 - "Secondary outcomes included the incidence of bradycardia, hypertension, hypotension, severe hypotension, hypotensive episodes, number of rescue top-ups, hemodynamic performance error including median performance error (MDPE), and median absolute performance error (MDAPE). " 01/01/2021 - "Secondary outcomes included the overall stability of SBP control versus baseline (median performance error [MDPE] and median absolute performance error [MDAPE]), the dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients, other adverse events (bradycardia, nausea, vomiting, hypertension, and the total additional bolus of norepinephrine and atropine), and neonatal outcomes (blood gas values and Apgar scores). "
3.	Bradycardia 12/01/2019 - "Secondary outcomes included the incidence of bradycardia, hypertension, hypotension, severe hypotension, hypotensive episodes, number of rescue top-ups, hemodynamic performance error including median performance error (MDPE), and median absolute performance error (MDAPE). " 01/01/2021 - "Secondary outcomes included the overall stability of SBP control versus baseline (median performance error [MDPE] and median absolute performance error [MDAPE]), the dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients, other adverse events (bradycardia, nausea, vomiting, hypertension, and the total additional bolus of norepinephrine and atropine), and neonatal outcomes (blood gas values and Apgar scores). "
4.	Vomiting 01/01/2021 - "Secondary outcomes included the overall stability of SBP control versus baseline (median performance error [MDPE] and median absolute performance error [MDAPE]), the dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients, other adverse events (bradycardia, nausea, vomiting, hypertension, and the total additional bolus of norepinephrine and atropine), and neonatal outcomes (blood gas values and Apgar scores). "
5.	Nausea 01/01/2021 - "Secondary outcomes included the overall stability of SBP control versus baseline (median performance error [MDPE] and median absolute performance error [MDAPE]), the dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients, other adverse events (bradycardia, nausea, vomiting, hypertension, and the total additional bolus of norepinephrine and atropine), and neonatal outcomes (blood gas values and Apgar scores). "

Related Drugs and Biologics

1.	Norepinephrine (Noradrenaline)
2.	Atropine

Related Therapies and Procedures

1.	Anesthesia
2.	Critical Care (Surgical Intensive Care)